In AD, several studies have shown that higher levels of tau biomarkers are more strongly associated with clinical AD and disease progression in women than in men; however, it is unknown whether these sex differences apply to plasma p-tau181 (42–45). The gene discussed is MAPT; the disease is Alzheimer disease.